Cedars-Sinai Discovery May Aid Doctors in Diagnosing At-risk Patients Before Symptoms Appear
A team led by a Cedars-Sinai physician-scientist has discovered a biomarker—a protein found in the blood—for the most common type of heart failure, a new study published today in JAMA Cardiology shows.
Heart failure with preserved ejection fraction (HFpEF) affects more than 6.5 million Americans each year. And now, thanks to the discovery of the first-ever biomarker for HFpEF, a simple blood test can reveal whether a patient’s heart is not making enough of an important protein. If the protein levels are decreased, the biomarker signal increases and physicians will be able to diagnose heart failure sooner, prescribe corrective medicines and prevent further disease progression.
“By the time heart failure symptoms develop, the critical window for corrective therapy has typically closed,” said Robin Shaw, MD, PhD, the Wasserman Endowed Chair in Cardiology and professor of Medicine at the Smidt Heart Institute at Cedars-Sinai and principal investigator on the study. “Our discovery allows us to not only diagnose the disease sooner, but also to treat patients before that critical period of early intervention for lifesaving care has closed.”
Heart failure with preserved ejection fraction is a condition where the heart can contract, but has problems relaxing—limiting the heart’s ability to fill with blood between each beat—and therefore lowers the amount of blood moving forward with each contraction. Prior to the discovery of the biomarker, clinicians had to wait for patients to have symptoms to make a diagnosis of HFpEF and had to use an echocardiogram that measured how well the heart relaxed. There was no method to gauge the health of the heart muscle before symptoms developed or determine the severity of disease once symptoms were present.
The biomarker—named cBIN1 Score, or CS for short—allows doctors to measure muscle deterioration and measure a protein that regulates the heart’s ability to both contract and relax. As the protein decreases, CS increases, serving as an indication of onset heart failure. The CS biomarker can be measured using a simple blood draw.
This discovery will allow the most at-risk patients—including older patients and patients with high blood pressure, diabetes or dyslipidemia—to be checked during an annual exam from their primary care physician. This pivotal research has the potential to impact millions of people and serve as a critical tool for preventive heart care.
Eduardo Marbán, MD, PhD, director, Smidt Heart Institute
The CS biomarker is designed to be used in an outpatient clinic setting. For patients with known HFpEF, doctors can draw a CS level and use it to both guide current care, including medication adjustments, and predict the chances of a patient being admitted to the hospital in the next 12 months.
“More broadly, this discovery will allow the most at-risk patients—including older patients and patients with high blood pressure, diabetes or dyslipidemia—to be checked during an annual exam from their primary care physician,” said Eduardo Marbán, MD, PhD, director of the Smidt Heart Institute. “This pivotal research has the potential to impact millions of people and serve as a critical tool for preventive heart care.”
Symptoms of heart failure typically appear as fatigue, fluid weight gain, leg swelling and shortness of breath. Heart failure with preserved ejection fraction is typically diagnosed in elderly people or those living with high blood pressure, diabetes, elevated cholesterol, hypertension, obesity, obstructive sleep apnea, anemia, iron deficiency or diabetes. Its prevalence is projected to rise drastically over the coming decades. Previous studies have shown that women represent the majority of patients diagnosed with the disease.
As next steps, Cedars-Sinai researchers plan on identifying specialty populations in which the CS biomarker could be useful, including sex-based differences, those who have undergone a heart transplant or valve replacement, as well as individuals with no known heart disease or risk factors.
Receive an email update when we add a new HEART FAILURE article.
The Latest on: Heart failure
via Google News
The Latest on: Heart failure
- Coronary calcium screening better predicts heart disease risk, research finds on November 12, 2018 at 3:29 pm
(CNN) - Last year, President Donald Trump's doctors screened him for heart disease using a test unfamiliar to many Americans. Now, research shows that that test, either alone or combined with other ev... […]
- Cancer May Soon Replace Heart Disease as Leading Killer of Affluent Americans on November 12, 2018 at 2:43 pm
MONDAY, Nov. 12, 2018 (HealthDay News) -- Cancer is expected to overtake heart disease as the leading cause of death for well-off Americans by 2020. The expected shift owes to advances in ... […]
- Cancer surpasses heart disease as leading cause of death in many US counties on November 12, 2018 at 2:01 pm
An important transition is happening across the United States: Cancer was the leading cause of death in more counties in 2015 than 13 years earlier, a new study finds. However, the opposite was true f... […]
- Patients with common heart failure more likely to have lethal heart rhythms on November 12, 2018 at 1:07 pm
Researchers at the Smidt Heart Institute at Cedars-Sinai discovered that a non-treatable form of lethal heart rhythm responsible for sudden cardiac arrest is twice as likely to be found in ... […]
- PIONEER-HF: Sacubitril/Valsartan Bests ACE Inhibitor for Biomarker Benefit in Stabilized Acute Heart Failure on November 12, 2018 at 12:23 pm
CHICAGO — If sacubitril/valsartan (Entresto, Novartis) remains slow to catch on in chronic heart failure (HF), despite earning support in the guidelines after the PARADIGM-HF trial, a new randomized t... […]
- Risk score-guided care reduces mortality rate in heart failure patients by nearly 50 percent on November 12, 2018 at 12:04 pm
New team-based care guided by a personalized risk score for heart failure patients reduced the mortality rate of high-risk heart failure patients by nearly 50 percent, according to new research from t... […]
- Don't count on vitamin D or fish oil supplements to reduce your risk of cancer or heart disease on November 12, 2018 at 11:40 am
A widely anticipated study has concluded that neither vitamin D nor fish oil supplements prevent cancer or serious heart-related problems — such as heart attacks and strokes — in healthy older people. ... […]
- Diabetes drug might also ease heart failure risks on November 12, 2018 at 5:58 am
(HealthDay)—The diabetes drug Farxiga might do double-duty for patients, helping to ward off another killer, heart failure, new research shows. Type 2 diabetics who took Farxiga (dapagliflozin ... […]
- Diabetes drug might also ease heart failure risk on November 11, 2018 at 9:22 am
SUNDAY, Nov. 11, 2018-- The diabetes drug Farxiga might do double-duty for patients, helping to ward off another killer, heart failure, new research shows. Type 2 diabetics who took Farxiga saw their ... […]
via Bing News